Moderna Stock Price, News & Analysis

Moderna, Inc. (Nasdaq:MRNA) announced new findings regarding the effectiveness of its COVID-19 vaccine, demonstrating durable neutralizing antibodies against several variants, including Delta, for up to six months post-vaccination. The study highlights that 93% efficacy is maintained over this period, with most participants retaining detectable antibody levels. While a slight decrease in antibody levels was noted, especially in older individuals, many preserved their neutralizing activity. This data aims to inform health regulators about potential booster doses.

Moderna (Nasdaq: MRNA) has signed a Memorandum of Understanding with the Canadian government to establish a new mRNA vaccine manufacturing facility in Canada. This facility aims to enhance Canada's pandemic response capabilities and provide access to Moderna's vaccines for respiratory viruses, including COVID-19. CEO Stéphane Bancel emphasized the collaboration's significance in global public health, stating the company's commitment to leveraging mRNA technology. The partnership is expected to foster Moderna's presence in Canada and further develop its mRNA portfolio.

Moderna (Nasdaq: MRNA) has received provisional registration from Australia’s Therapeutic Goods Administration for its COVID-19 Vaccine, authorized for individuals aged 18 and over. Vaccine delivery is set to begin in September 2021. The Australian government secured 10 million doses for 2021 with an option for an additional 15 million in 2022. Aside from Australia, Moderna has received approvals from over 50 countries and the WHO for its vaccine. Ongoing evaluations for adolescent use are underway, highlighting the vaccine's broad acceptance and demand.

Moderna (Nasdaq: MRNA) reported Q2 2021 financial results with total revenue of $4.4 billion, a significant increase from $67 million in Q2 2020, driven primarily by COVID-19 vaccine sales. The company expects dose capacity to range from 800 million to 1 billion doses in FY 2021. Moderna's COVID-19 vaccine shows a durable efficacy of 93% over six months. The company is advancing multiple mRNA candidates across therapeutic areas, including upcoming Phase 3 trials for RSV and flu vaccines, and has received Fast Track designation for its RSV vaccine.

Moderna (Nasdaq: MRNA) announced that the FDA has granted Fast Track designation for its investigational mRNA-1345, a single-dose vaccine against respiratory syncytial virus (RSV) targeting adults over 60. The vaccine aims to protect vulnerable populations, such as older adults and young children, as RSV leads to significant hospitalizations and deaths annually. Moderna is conducting ongoing clinical trials for mRNA-1345 and plans to assess its combinations with other vaccines. The company has previously received Fast Track designations for several other vaccine candidates.

Moderna (Nasdaq: MRNA) has dosed its first participant in the Phase 1 study of mRNA-6231, its first autoimmune candidate designed to expand regulatory T cells. This marks a significant milestone as it is also the company's first subcutaneously administered therapeutic. The trial aims to evaluate the safety and tolerability of mRNA-6231 in healthy adults. Moderna continues to advance its mRNA platform with programs in various therapeutic areas, highlighting its commitment to addressing autoimmune diseases.

Moderna (MRNA) announced a positive recommendation from the European Medicines Agency’s CHMP for its COVID-19 vaccine, Spikevax, to include adolescents aged 12 and older. This follows the successful Phase 2/3 study showing 100% vaccine efficacy post-second dose in this age group. The European Commission will consider final authorization, which could help in the return to school for adolescents. The vaccine has been well-tolerated, with most adverse events being mild. Moderna is also conducting further studies for younger children.